Trust Co. of Toledo NA OH Sells 416 Shares of Pfizer Inc. $PFE

Trust Co. of Toledo NA OH reduced its stake in Pfizer Inc. (NYSE:PFE) by 0.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 153,930 shares of the biopharmaceutical company’s stock after selling 416 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Pfizer were worth $3,731,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Capital Advisory Group Advisory Services LLC increased its position in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 388 shares during the period. Citizens National Bank Trust Department increased its position in Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 395 shares during the period. Trust Co of the South increased its position in Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after acquiring an additional 441 shares during the period. Charter Oak Capital Management LLC increased its position in Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 444 shares during the period. Finally, Ballentine Partners LLC increased its holdings in shares of Pfizer by 0.5% during the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after purchasing an additional 458 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on PFE. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley decreased their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday. Bank of America raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.35.

Pfizer Stock Performance

Pfizer stock opened at $24.81 on Friday. The stock has a market cap of $141.03 billion, a PE ratio of 13.19, a P/E/G ratio of 0.83 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business’s 50-day moving average price is $24.86 and its two-hundred day moving average price is $24.14. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.82.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.